Stride Arcolab

Banking, financial, auto, pharma, liquor and paints sectors will be getting astrological support says Satish Gupta of Astrostocktips.

Stride Arcolab sells Generic biz; stock rises 13%

Stride Arcolab has sold Generic business in Southeast Asia and Australia for USD 400 million, reports CNBC-TV18.

Buy Stride Arcolab, says Sukhani

Sudarshan Sukhani, s2analytics.com is of the view that one can buy Stride Arcolab.

Buy Stride Arcolab; target Rs 464: Firstcall Research

Firstcall Research is bullish on Stride Arcolab and has recommended buy rating on the stock with a target of Rs 464 in its November 05, 2011 research report.

Bull's Eye: 12 stocks you can bet on Nov 4

Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

Accumulate Stride Arcolab; target of Rs 451: Dolat Capital

Dolat Capital is bullish on Stride Arcolab and has recommended accumulate rating on the stock with a target of Rs 451 in its October 25, 2011 research report.

Stride Arcolab Sep '11 sales at Rs 196.98 crore

Stride Arcolab has reported a sales turnover of Rs 196.98 crore and a net loss of Rs 65.19 crore for the quarter ended Sep '11

Pronomz Ventures buys 14.99% stake in Stride Arcolab

Stride Arcolab touched an intraday high of Rs 357.80 and an intraday low of Rs 352.25. At 09:52 hrs the share was quoting at Rs 353.10, up Rs 2.50, or 0.71%. Agnus Capital has bought 7.43% and Pronomz Ventures bought 14.99% stake in Stride Arcolab at Rs 105 per share, reports CNBC-TV18.

Stride Arcolab has target of Rs 352: Aashish Tater

Stride Arcolab has target of Rs 352, says Aashish Tater of Fort Share Broking.

Stride Arcolab Sept qtr PAT seen up 87% at Rs 30.5 cr

Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Stride Arcolab September quarter net sales are expected to go up by 27.1% at Rs 547 crore, year-on-year, (YoY) basis.

Bull's Eye: Buy Pipavav, VIP, Gitanjali Gema; short Sun TV

Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

Stride Arcolab arm gets US FDA nod; stock trading flat

Stride Arcolab arm has got US FDA nod to market Paclitaxel Injection, reports CNBC-TV18. It touched an intraday high of Rs 364 and an intraday low of Rs 350. At 11:20 hrs the share was quoting at Rs 356.05, up Re 1, or 0.28%.

Buy Stride Arcolab, says Sharmila Joshi

Buy Stride Arcolab, says Sharmila Joshi of Fairwealth Securities.

Bull's Eye: Short Sesa Goa, Educomp, Sterlite Ind; buy Eros

Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

Book profit in Stride Arcolab: Ashish Chaturmohta

Book profit in Stride Arcolab, says Ashish Chaturmohta of IIFL Wealth.

Strides Arcolab gains 3.7% on US FDA approval

Stride Arcolab oral dosage facility continues to receive approval from US FDA, reports CNBC-TV18. It touched an intraday high of Rs 299.70 and an intraday low of Rs 282.50. At 13:59 hrs the share was quoting at Rs 295, up Rs 10.75, or 3.78%.

Stride Arcolab Jun '11 sales at Rs 200.93 crore

Stride Arcolab has reported a sales turnover of Rs 200.93 crore and a net profit of Rs 14.61 crore for the quarter ended Jun '11

PN Vijay bets on BGR Energy, Stride Arcolab for 12-15 mths

PN Vijay, Portfolio Manager, in a discussion with CNBC-TV18's Udayan Mukherjee and Mitali Mukherjee, shared his views on the top picked stocks from the midcap and smallcap space.

Stride Arcolab has target of Rs 475: PN Vijay

Stride Arcolab has target of Rs 475, says PN Vijay, Portfolio Manager.

Buy Strides Arcolab: Jain

Buy Stride Arcolab with a target of Rs 400, says Rajesh Jain, Independent Market Strategist.

Buy Stride Arcolab; target of Rs 506: KRChoksey

KRChoksey is bullish on Stride Arcolab and has recommended buy rating on the stock with a target of Rs 506 in its April 28, 2011 research report.

Stride Arcolab gets US FDA nod; stock down

Stride Arcolab has got US FDA nod for Oncology unit in Bengaluru, reports CNBC-TV18. It touched an intraday high of Rs 397.80 and an intraday low of Rs 375.30. At 09:57 hrs the share was quoting at Rs 379.60, down Rs 5.65, or 1.47%.

Buy Stride Arcolab; target of Rs 473: Motilal Oswal

Motilal Oswal is bullish on Stride Arcolab and has recommended buy rating on the stock with a target of Rs 473 in its April 25, 2011 research report.

Stride Arcolab Mar '11 sales at Rs 127.94 crore

Stride Arcolab has reported a sales turnover of Rs 127.94 crore and a net profit of Rs 12.74 crore for the quarter ended Mar '11

Stride Arcolab targets Rs 2200cr revenue in 2011

Stride Arcolab has declared its first quarter results. The company's Q1 consolidated net profit was up 2.26% at Rs 40.7 crore versus Rs 39.8 crore. For 2011, he says, “A median EBITDA of 21% is the one we are looking at the increased sales of Rs 2,200 crore.”